Active third-party funding
H2B: IMPACT - Economic Perspectives on the Bremen Hydrogen Valley
Duration: 2026 to 2030
Project financed Staff: Julian Wilches (scientific employee PhD candidate)
The University of Bremen participates in H2B through the Faculty of Business Studies and Economics. As part of the consortium, the Faculty contributes an economic perspective on the development of the Bremen Hydrogen Valley and supports the assessment of hydrogen applications in road transport, port logistics, non-road machinery, and e-fuels.
H2B brings together partners from research, industry, infrastructure, and public institutions to advance an integrated regional hydrogen ecosystem in Bremen and Bremerhaven. The project connects hydrogen production, distribution, refuelling infrastructure, and end-use applications through several real-life testbeds. These include hydrogen vehicles, port equipment, mobile refuelling solutions, construction machinery, and hydrogen-based fuel production.
Within this consortium, the Faculty of Business Studies and Economics examines how hydrogen applications can move from demonstration to broader market uptake. Its contribution focuses on economic viability, business-case conditions, potential hydrogen use, and long-term scale-up pathways. The work links evidence from the project’s testbeds with questions of infrastructure planning, market formation, and regional development.
By contributing economic analysis to H2B, the Faculty supports the consortium in developing an evidence base for Bremen’s hydrogen economy and the future Hydrogen Economy Roadmap. The project also strengthens the Faculty’s research on innovation, structural change, and the economic conditions of green technology transitions.
Contact: Julian Wilches
Fixed Drug Prices—Competition and Regulatory Economics Perspectives on the German Pharmacy Market
Duration: June 2026 to Mai 2027
Staff members funded by the project / Project team: Dr. Jan Thomas Schäfer, M.A., Dr. Daniel Herold, M.Sc.
The University of Bremen is conducting a research project to analyze price fixing for prescription human medications in Germany. The project is being carried out in cooperation with Justus Liebig University Giessen and is funded by the Westfalen-Lippe Pharmacists' Association. As part of the project, the effectiveness of existing price regulation will be examined from the perspectives of competition and regulatory economics in the context of specific regulatory characteristics and discussed in light of health policy objectives.
The project is based on the European Court of Justice’s ruling (C-148/15), which overturned Germany’s ban on bonuses for foreign mail-order pharmacies. Since the Court found that there was insufficient evidence to show that free price competition would, for example, jeopardize comprehensive emergency care in Germany, the project links this legal framework to a thorough analysis of the market imperfections that are likely to exist in the pharmaceutical sector.
The research team is examining which mechanisms are best suited to ensuring health policy goals are met in the German context, and how current regulations should be evaluated. The focus is on counterfactual scenarios, such as the complete abolition of fixed pricing, as well as on other regulatory requirements, such as the prohibition on multiple ownership. The analysis examines how free price competition between brick-and-mortar and mail-order pharmacies—as well as within these two groups—would play out. Methodologically, the studies address these questions using an empirical-econometric approach from the consumers’ perspective: In particular, the study examines the extent to which consumers react to price differences and when they switch pharmacies or sales channels
Through its open-ended analysis conducted in accordance with the principles of sound scientific practice, the chair establishes a robust evidence base for scientific and policy discussions on pharmaceutical supply. By publishing in peer-reviewed journals, the project also strengthens the department’s research on market regulation, consumer behavior, and economic conditions in the healthcare system.
